EXOZ

eXoZymes Inc. Common Stock

10.46 USD
+0.34
3.36%
Updated Apr 3, 2:16 PM EDT
1 day
3.36%
5 days
4.08%
1 month
-38.14%
3 months
-28.26%
6 months
20.92%
Year to date
-29.37%
1 year
20.92%
5 years
20.92%
10 years
20.92%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

1.21% more ownership

Funds ownership: 0% [Q3] → 1.21% (+1.21%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for EXOZ.

Financial journalist opinion

Based on 3 articles about EXOZ published over the past 30 days

Neutral
GlobeNewsWire
23 hours ago
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Expanded leadership team as eXoZymes ramps up commercial growth Damien Perriman brings more than two decades of experience in successfully developing and commercializing novel biotechnologies Focus on developing commercial opportunities, spin-outs, joint-ventures, and licensing deals with future partners Monrovia, CA, April 02, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - announced the appointment of Damien Perriman to a newly created role as Chief Commercial Officer (CCO). Perriman brings more than two decades of experience in successfully commercializing several biotechnologies, spanning diverse markets such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals.
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Neutral
GlobeNewsWire
23 hours ago
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
Management to Host Conference Call Today at 4:30PM Eastern
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
Neutral
GlobeNewsWire
1 week ago
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
Monrovia, CA , March 26, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - plans to host a webinar on Wednesday, April 2, 2025 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2024. A press release detailing these results will be issued prior to the call.
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
Charts implemented using Lightweight Charts™